KeratoScoop (Rebecca's blog)

Somehow outperforming Restasis sounds rather inevitable than impressive in this context, but nonetheless the drug sounds promising.

Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease: Results from a Phase 1/2 Trial.

OBJECTIVE:
To evaluate safety and efficacy of topical ophthalmic tofacitinib (CP-690,550), a novel Janus kinase inhibitor, in treating dry eye disease (DED).

DESIGN:
A phase 1/2 prospective, randomized, double-masked,

...